250,000 Shares in Alto Neuroscience, Inc. (NYSE:ANRO) Acquired by Orbimed Advisors LLC

Orbimed Advisors LLC bought a new position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 250,000 shares of the company's stock, valued at approximately $1,058,000. Orbimed Advisors LLC owned 0.93% of Alto Neuroscience at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Wells Fargo & Company MN raised its stake in Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock worth $46,000 after buying an additional 3,139 shares in the last quarter. Deutsche Bank AG raised its stake in Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock worth $64,000 after buying an additional 3,629 shares in the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in Alto Neuroscience in the fourth quarter worth about $74,000. Jane Street Group LLC raised its stake in Alto Neuroscience by 72.0% in the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after buying an additional 7,783 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock worth $108,000 after buying an additional 5,008 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Wedbush reaffirmed a "neutral" rating and set a $4.00 target price on shares of Alto Neuroscience in a research note on Thursday. HC Wainwright assumed coverage on shares of Alto Neuroscience in a research note on Monday, April 7th. They set a "buy" rating and a $10.00 target price for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.40.

Alto Neuroscience Stock Up 5.0%

Shares of ANRO traded up $0.12 on Friday, hitting $2.55. 217,225 shares of the stock traded hands, compared to its average volume of 384,765. The company has a market capitalization of $69.06 million, a PE ratio of -1.09 and a beta of 1.87. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The business has a 50 day simple moving average of $2.37 and a 200 day simple moving average of $3.43. Alto Neuroscience, Inc. has a one year low of $1.60 and a one year high of $17.55.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.06. As a group, equities analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.